Laboratoire Cooperatif "Lipotoxicity and Channelopathies-ConicMeds", Universite de Poitiers, Rue Georges Bonnet, 86073 Poitiers, France.
Facultede Medecine, Universite Paris-Saclay, 94270 Le Kremlin-Bicêtre, France.
Biomolecules. 2022 Dec 14;12(12):1878. doi: 10.3390/biom12121878.
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary arterial hypertension (PAH) occurring in a heritable form (hPVOD) due to biallelic inactivating mutations of (encoding GCN2, general control nonderepressible 2) or in a sporadic form in older age (sPVOD), following exposure to chemotherapy or organic solvents. In contrast to PAH, PVOD is characterized by a particular remodeling of the pulmonary venous system and the obliteration of small pulmonary veins by fibrous intimal thickening and patchy capillary proliferation. The pathobiological knowledge of PVOD is poor, explaining the absence of medical therapy for PVOD. Lung transplantation remains the only therapy for eligible PVOD patients. As we recently demonstrated, respiratory diseases, chronic obstructive pulmonary disease, or cystic fibrosis exhibit lipointoxication signatures characterized by excessive levels of saturated phospholipids contributing to the pathological features of these diseases, including endoplasmic reticulum stress, pro-inflammatory cytokines production, and bronchoconstriction. In this study, we investigated and compared the clinical data and lung lipid signature of control (10 patients), idiopathic PAH (7 patients), heritable PAH (9 mutations carriers), hPVOD (10 mutation carriers), and sPVOD (6 non-carriers) subjects. Mass spectrometry analyses demonstrated lung lipointoxication only in hPVOD patients, characterized by an increased abundance of saturated phosphatidylcholine (PC) at the expense of the polyunsaturated species in the lungs of hPVOD patients. The present data suggest that lipointoxication could be a potential player in the etiology of PVOD.
肺静脉闭塞病(PVOD)是一种罕见的肺动脉高压(PAH)形式,以常染色体隐性遗传形式(hPVOD)发生,由 (编码 GCN2,一般控制非抑制 2)的双等位基因失活突变引起,或在老年时以散发性形式(sPVOD)发生,继发于化疗或有机溶剂暴露。与 PAH 不同,PVOD 的特征是肺静脉系统的特定重塑,以及小肺静脉被纤维内膜增厚和斑片状毛细血管增生所闭塞。PVOD 的病理生物学知识很差,这解释了为什么没有针对 PVOD 的药物治疗。肺移植仍然是符合条件的 PVOD 患者的唯一治疗方法。正如我们最近所证明的,呼吸疾病、慢性阻塞性肺疾病或囊性纤维化表现出脂毒性特征,其特征是过量的饱和磷脂,导致这些疾病的病理特征,包括内质网应激、促炎细胞因子的产生和支气管收缩。在这项研究中,我们研究并比较了对照组(10 名患者)、特发性 PAH(7 名患者)、遗传性 PAH(9 个 突变携带者)、hPVOD(10 个 突变携带者)和 sPVOD(6 个非携带者)患者的临床数据和肺脂质特征。质谱分析表明,只有 hPVOD 患者存在肺脂毒性,其特征是肺部饱和磷脂酰胆碱(PC)的丰度增加,而多不饱和物种的丰度减少。目前的数据表明,脂毒性可能是 PVOD 病因的一个潜在因素。